New Data from Marius Pharmaceuticals Reveals High Prevalence of Low Libido, Energy and Quality of Life in Men RALEIGH, N.C., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a pharmaceutical company focused on developing innovative therapies for testosterone deficiency, has released compelling new...

Marius Pharmaceuticals Submits KYZATREX® (Testosterone Undecanoate) CIII Capsules for Approval to Health Canada RALEIGH, N.C., July 30, 2024 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a patient-centric healthcare company focused on developing innovative therapies for Testosterone Deficiency, is pleased to...

Marius Pharmaceuticals Supports AXYS 2023 Virtual Family Conference, Spotlighting KYZATREX™ for XY Chromosome Variations, such as Klinefelter’s Syndrome RALEIGH, N.C., June 20, 2023 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a patient-centric healthcare company specializing in therapies for hypogonadism or testosterone deficiency, announced today...

Male Hypogonadism Market to Reach $5.1 Billion by 2030, Claims Allied Market Research Portland, OR, June 28, 2022 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global male hypogonadism market generated $3.1 billion in 2020, and is expected to...